Want to see HK:1858 full AI Analyst Report?
1858 Stock Chart & Stats
HK$15.39
-HK$0.21(-2.63%)
At close: 4:00 PM EST
HK$15.39
-HK$0.21(-2.63%)
Day’s Range― - ―
52-Week RangeHK$7.01 - HK$20.82
Previous CloseN/A
Volume218.00K
Average Volume (3M)495.29K
Market Cap
HK$5.14B
Enterprise ValueHK$808.40M
Total Cash (Recent Filing)HK$2.13B
Total Debt (Recent Filing)HK$3.06M
Price to Earnings (P/E)18.2
Beta0.96
Next Earnings
Mar 29, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.51%
Share Statistics
EPS (TTM)0.72
Shares Outstanding95,140,500
10 Day Avg. Volume388,600
30 Day Avg. Volume495,293
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.71
Price to Sales (P/S)4.89
P/FCF Ratio14.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.76
Revenue Forecast (FY)HK$1.07B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityThe company’s high gross, net, and EBIT margins indicate strong profitability across its operating structure. This provides capacity to absorb cost pressure, fund research and development, support commercial investment, and preserve earnings resilience over the next several quarters.
Very Low LeverageExtremely low leverage materially reduces interest burden and refinancing exposure, while preserving flexibility to invest or withstand weaker demand. The stable equity base also provides a substantial financial cushion, supporting resilience through the medium term.
Positive Current Cash GenerationPositive operating and free cash flow show that reported earnings are currently converting into cash at a solid rate. This supports internally funded operations, investment capacity, and shareholder distributions without relying heavily on external financing.
Bears Say
Softening Revenue MomentumThe recent revenue decline and uneven annual pattern indicate that demand growth is not yet consistently established. If this choppiness persists, it could limit operating leverage, reduce growth investment capacity, and make future earnings expansion less predictable.
Volatile Cash ConversionAlthough current cash generation is positive, the history of negative 2024 cash flow and the sharp TTM decline versus 2025 show inconsistent conversion. Working-capital or investment swings can therefore affect funding flexibility and make cash-based performance less dependable.
Variable Return On EquityThe change in return on equity shows that the company’s sizable capital base has not produced equally consistent profitability across periods. Lower returns in weaker years may constrain efficient capital deployment and signal that earnings quality can fluctuate despite low leverage.
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H News
1858 FAQ
What was Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s price range in the past 12 months?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H lowest stock price was HK$7.01 and its highest was HK$20.82 in the past 12 months.
What is Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s market cap?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s market cap is HK$5.14B.
When is Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s upcoming earnings report date?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s upcoming earnings report date is Mar 29, 2027 which is in 150 days.
How were Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s earnings last quarter?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H released its earnings results on Oct 30, 2026. The company reported HK$0.212 earnings per share for the quarter.
Is Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H overvalued?
According to Wall Street analysts Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s price is currently Overvalued.
Does Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H pay dividends?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H pays a Semiannually dividend of HK$0.172 which represents an annual dividend yield of 5.51%. See more information on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H dividends here
What is Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s EPS estimate?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H have?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H has 95,140,500 shares outstanding.
What happened to Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H’s price movement after its last earnings report?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H reported an EPS of HK$0.212 in its last earnings report. Following the earnings report the stock price went down -1.626%.
Which hedge fund is a major shareholder of Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1858
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.30%
12-Months-Change
Fundamentals
Return on Equity
9.20%
Trailing 12-Months
Asset Growth
8.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
Beijing Chunlizhengda Medical Instruments Co., Ltd. functions as a prominent entity within the orthopedic medical device industry, dedicated to the development, manufacturing, and distribution of surgical implants, instruments, and associated medical supplies throughout the People's Republic of China. Its core product range features implantable orthopedic solutions, specifically comprising joint prostheses and spinal treatment products. The company predominantly distributes its merchandise via an expansive network of distributors, through original design manufacturing (ODM) and original equipment manufacturing (OEM) partnerships under the 'Chunli' label, and by direct sales to healthcare institutions. Beyond its domestic operations, the firm also engages in exporting its products to various countries globally. Established in 1998, its corporate headquarters are situated in Beijing, China.
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) Earnings & Revenues
Technical Analysis
MicroPort Scientific
―
Peijia Medical Ltd.
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―